研究者データベース

大橋 和貴(オオハシ カズキ)
保健科学研究院 保健科学部門 基盤看護学分野
助教

基本情報

所属

  • 保健科学研究院 保健科学部門 基盤看護学分野

職名

  • 助教

学位

  • 修士(保健学)(新潟大学)
  • 学士(看護学)(新潟大学)

J-Global ID

研究キーワード

  • リハビリテーション看護   NAFLD   肝硬変   骨格筋   QOL   身体活動量   

研究分野

  • ライフサイエンス / 臨床看護学

職歴

  • 2021年10月 - 現在 北海道大学大学院保健科学研究院 基盤看護学分野 助教
  • 2019年04月 - 2021年09月 札幌保健医療大学 保健医療学部 看護学科 助教
  • 2013年04月 - 2019年03月 済生会新潟病院 看護部 看護師

学歴

  • 2016年04月 - 2019年03月   新潟大学大学院   保健学研究科   保健学専攻博士前期課程
  • 2006年04月 - 2010年03月   新潟大学   医学部   保健学科看護学専攻

所属学協会

  • 日本医療情報学会   日本肝臓学会   日本サルコペニア・フレイル学会   日本慢性看護学会   日本医療マネジメント学会   

研究活動情報

論文

  • Kazuki Ohashi, Kensuke Fujiwara, Toshiya Osanai, Takumi Tanikawa, Kyohei Bando, Shojiro Yamasaki, Tomohiro Aoki, Songzi Gu, Katsuhiko Ogasawara
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 31 9 106625 - 106625 2022年07月04日 [査読有り]
     
    OBJECTIVES: This study aimed to evaluate a stroke medical delivery system based on population coverage and the potential crowdedness index (PCI) of mechanical thrombectomy and investigate the relationship between PCI and cerebral infarction mortality in Japan. MATERIALS AND METHODS: This cross-sectional study defined 662 facilities and 1605 neurointerventionalists as supply, population aged 55 years or older as demand, and set the reachable area for demand as 120 min in driving time. Multiple regression analysis adjusted for spatial autocorrelation was used to examine the relationship between PCI and cerebral infarction mortality. RESULTS: In the 2020 data, 99% of the population aged 55 years or older had access to mechanical thrombectomy (≤120 min), and the PCI ranged from 5876 to 129838, with a median of 30426. From 2020 to 2035, the PCI is estimated to increase (30426 to 32510), decreasing after 2035 (32510 to 29469). The PCI distribution exhibited geographical heterogeneity. High PCI values emerged in eastern Japan. According to regression analysis, the increase in PCI by 1% led to an increase of 0.13% in standardized mortality ratio of cerebral infarction in men. However, PCI did not significantly correlate with cerebral infarction mortality in women. CONCLUSIONS: PCI for hospitals based on supply and demand was geographically heterogeneous in Japan. Optimization of PCI contributes equalization of mechanical thrombectomy provision system and may improve cerebral infarction mortality.
  • Kazuki Ohashi, Kensuke Fujiwara, Takumi Tanikawa, Kyohei Bando, Tomohiro Aoki, Katsuhiko Ogasawara
    Geospatial health 17 1 2022年05月16日 [査読有り]
     
    The increasing demand for long-term care (LTC) among the ageing population is a serious problem worldwide, which has greatly increased also in Japan since the introduction of the LTC insurance system there. Since there is a difference between insurers with respect to the proportion of people needing LTC, this study aimed at clarifying the spatial patterns of LTC. Insurer (n=156) LTC data for the period 2012-2019 were obtained from Ministry of Health, Labour, and Welfare and those needing LTC were classified into three classes: total, mild and severe with ageand sex-adjusted proportions needing LTC. Global and local Moran’s I statistics were calculated for each 2-year period to clarify the trends of global and local spatial clusters. From 2012 to 2019, the mean proportion of mild class cases increased (10.6% to 11.6%), whereas that of severe class cases decreased slightly (5.9% to 5.7%). The spatial pattern of the proportion of each class revealed positive spatial autocorrelation. Based on analysis by local Moran’s I, differences in spatial patterns were emphasised between the mild and severe classes. In Hokkaido, High-High clusters of mild cases were identified in the central and southern parts and severe ones in the northern and southern parts. Spatial patterns differed depending on the LTC class. Some insurers had distinctly higher or lower certification rates than those of their neighbourhoods.
  • Toru Ishikawa, Kazuki Ohashi, Erina Kodama, Takamasa Kobayashi, Motoi Azumi, Yujiro Nozawa, Akito Iwanaga, Tomoe Sano, Terasu Honma
    Gastro Hep Advances 1 3 431 - 436 2022年 [査読有り]
  • Kazuki Ohashi, Madoka Ito, Megumi Kawakubo, Ikue Sato
    Healthcare 9 8 1021 - 1021 2021年08月09日 [査読有り]
     
    Sarcopenia is associated with poor prognosis and decreased quality of life in patients with chronic liver disease (CLD). The present study aimed to clarify the dissemination of interventions such as evaluations, prevention efforts, and treatments for sarcopenia among patients in hepatology outpatient departments and wards in Japan, as well as examine the factors related to such dissemination. A cross-sectional study was performed involving nurses from hospitals accredited by the Japan Society of Hepatology. Participants completed a questionnaire regarding evaluations and interventions for sarcopenia in their department. Nurses from 72 outpatient departments and 162 wards provided responses to the questionnaire. Overall, 37.9% of outpatient departments and 37.6% of wards performed evaluations or interventions for sarcopenia. Outpatient departments and wards that evaluated sarcopenia or intervened held more workshops or training regarding sarcopenia than departments and wards that did not (outpatient departments: 52.0% vs. 12.2%, wards: 32.1% vs. 12.9%). Holding workshops or training regarding sarcopenia (outpatient departments; OR = 7.51, 95% confidence interval (CI): 2.12–26.6, wards; OR = 2.61, 95% CI: 1.11–6.15) was significantly associated with dissemination practices. These findings suggest that expanding knowledge of sarcopenia and developing practical skills among general nurses may aid in preventing sarcopenia among patients with CLD.
  • Kazuki Ohashi, Toru Ishikawa, Asami Hoshii, Tamaki Hokari, Hirohito Noguchi, Mitsuyuki Suzuki, Hiroshi Hirosawa, Michitaka Imai, Yuta Mitobe, Toshiaki Yoshida
    Journal of clinical medicine 10 7 2021年04月01日 [査読有り]
     
    Although dual-energy X-ray absorptiometry (DXA) and body impedance analysis are commonly used to measure skeletal muscle mass (SMM), a computed tomography (CT) scan is preferred in clinical practice. We aimed to propose the cut-off values of skeletal muscle mass index (SMI) calculated using CT scans, using DXA as the reference method. We retrospectively assessed 589 patients with chronic liver disease. The SMI was assessed using appendicular SMM by DXA and total muscle area at the level of the third lumbar vertebra (L3) calculated by CT. The cut-off value was determined with reference to the Asian Working Group for Sarcopenia criteria. DXA identified 251 (42.6%) patients as having presarcopenia. In men, the cut-off value of SMI for presarcopenia was determined to be 45.471 cm2/m2, with an area under the curve (AUC) of 0.863 (95% confidence interval (CI): 0.823 to 0.903), and in women, this value was determined to be 35.170 cm2/m2, with an AUC of 0.846 (95% CI: 0.800 to 0.892). Cohen's kappa coefficient was 0.575 (95% CI: 0.485-0.665) in men and 0.539 (95% CI: 0.438-0.639) in women.
  • Kazuki Ohashi, Toru Ishikawa, Asami Hoshii, Tamaki Hokari, Mitsuyuki Suzuki, Hirohito Noguchi, Hiroshi Hirosawa, Fujiko Koyama, Miki Kobayashi, Shiori Hirosawa, Kaede Sugiyama, Yuta Mitobe, Toshiaki Yoshida
    Experimental and therapeutic medicine 20 5 94 - 94 2020年11月 [査読有り][通常論文]
     
    L-carnitine administration was reported to improve sarcopenia in patients with cirrhosis. However, the amount of evidence from previous studies is not sufficient. The present study aimed to clarify the effect of levocarnitine (L-carnitine) administration on body composition in patients with chronic liver disease (CLD). In the present study, 85 patients with L-carnitine administration and 87 control patients were enrolled and divided them into two groups, the L-carnitine administration group (LAG, n=44) and the without L-carnitine administration (controls, n=44) group, by using propensity score matching for age, sex, body mass index (BMI) and serum albumin. Δ skeletal muscle mass index (SMI)/year, Δ intramuscular adipose tissue content (IMAC)/year and Δ bone mineral density (BMD)/year were examined during L-carnitine administration. Each parameter was measured by computed tomography (CT) or dual-energy X-ray absorptiometry. The median age overall was 69 years (IQR, 64.0, 75.0); 36 were men and 52 were women. The median SMI was 37.4 cm2/m2 (IQR, 34.01, 44.34). The initial CT scans showed similar median values of SMI for the two groups [37.74 (34.17, 43.58) and 37.16 (33.83, 44.34), P=0.67]. However, the median ΔSMI/year for the LAG and controls were 0.95% (-3.07, 6.10) and -2.34% (-5.34, 0.53), respectively (P=0.003). The median Δ whole body BMD/year for the LAG and controls were -0.24% (-1.20, 0.91) and -1.04% (-2.16, 0.47), respectively (P=0.038). The median ΔIMAC/year and Δ lumbar spine BMD were not significantly different between the LAG and controls. L-carnitine administration may prevent the loss of skeletal muscle mass and BMD; therefore, it may be used as a new treatment option for osteoporosis and sarcopenia in patients with CLD.
  • Yuta Mitobe, Shinichiro Morishita, Kazuki Ohashi, Sayuri Sakai, Mieko Uchiyama, Hansani Abeywickrama, Etsuko Yamada, Yuko Kikuchi, Masakazu Nitta, Tadayuki Honda, Hiroshi Endoh, Shinji Kimura, Shuhei Sakano, Yu Koyama
    Journal of clinical medicine research 11 12 834 - 841 2019年12月 [査読有り][通常論文]
     
    Background: Intensive care unit-acquired weakness (ICU-AW) can be diagnosed using the Medical Research Council (MRC) score. However, such scoring may not be possible in ICU patients who may be sedated or delirious or have encephalopathy. Currently, a quantitative assessment of the cross-sectional area of the muscle is available to assess changes in skeletal muscle mass using computed tomography (CT) images. This assessment calculates the skeletal muscle index (SMI) (cm2/m2) by dividing the cross-sectional area (cm2) of the skeletal muscle at the level of the third lumbar vertebra by the square of the patient's height (m2) on CT. This study assessed the effectiveness of SMI, as measured by abdominal CT scans, in predicting the onset of ICU-AW in patients with sepsis admitted to the ICU. Methods: We examined septic ICU patients admitted to the Niigata University Hospital ICU during 2012 - 2017 under mechanical ventilation. Patients were retrospectively divided into two groups by MRC score at ICU discharge: group AW comprised patients with an MRC score < 48, and group non-AW (NAW) comprised the remaining patients. Clinicopathological factors at ICU admission such as age, gender, underlying disease, body mass index, and SMI were compared between the two groups. Statistical analyses were performed using the Mann-Whitney U test, Fisher's exact test, receiver operator characteristic (ROC) analysis and multivariate analysis. Results: A total of 31 septic patients were examined, and 23 patients met the criteria for ICU-AW. The prevalence of women was significantly higher in group AW (P < 0.05). All clinical factors, except for gender, were not significantly different between the two groups. SMI was significantly lower in group AW than in group NAW (P < 0.05). ROC analysis revealed that the cut-off value of SMI for predicting ICU-AW was 44.1, and the multivariate analysis revealed that only low SMI was a significant factor in predicting ICU-AW (P < 0.05). Conclusions: Our results show that SMI measurement at ICU admission is a valid predictive factor for ICU-AW progression in septic patients.
  • Kazuki Ohashi, Toru Ishikawa, Michitaka Imai, Mitsuyuki Suzuki, Asami Hoshii, Hiroko Abe, Fujiko Koyama, Tomomi Nakano, Aya Ueki, Hirohito Noguchi, Erina Hasegawa, Shiori Hirosawa, Miki Kobayashi, Hiroshi Hirosawa, Kaede Sato, Miyu Munakata, Toshiaki Yoshida
    European journal of gastroenterology & hepatology 31 11 1408 - 1413 2019年11月 [査読有り][通常論文]
     
    AIM: This study aimed to clarify the relationship between pre-sarcopenia (PS) and quality of life (QOL) in patients with chronic liver disease (CLD). PATIENTS AND METHODS: This cross-sectional study evaluated 335 patients with CLD. PS was diagnosed on the basis of the assessment criteria by the Japan Society of Hepatology. QOL was evaluated using the short form-36. RESULTS: Patients' mean age was 69.52 ± 10.17 years, and 169 (50.4%) participants were men. The prevalence of PS was 53.7%. Patients were divided into the PS and non-pre-sarcopenia (NPS) groups. Patients in the PS group were older (71.84 ± 9.78 vs. 66.81 ± 9.97, P < 0.01) and mostly women (65.2 vs. 37.8%, P < 0.01) compared with those in the NPS group. QOL, physical function (38.30 ± 17.63 vs. 44.02 ± 14.76, P < 0.01), physical role functioning (RP) (40.63 ± 15.38 vs. 44.88 ± 13.89, P < 0.01), and bodily pain (BP) (48.42 ± 11.45 vs. 51.24 ± 10.19, P = 0.02) were significantly lower in the PS group than in the NPS group. Logistic regression analyses identified that the independent predictive factors for PS were female sex (odds ratio: 3.16, 95% confidence interval: 2.01-4.98; P < 0.01) and RP (odds ratio: 1.97, 95% confidence interval: 1.24-3.12; P < 0.01). CONCLUSION: QOL characteristics of PS patients with CLD were low physical function, RP, and BP in short form-36. In addition, social role functioning was low in the PS patients aged 65-74 years, whereas RP and BP were low in those aged at least 75 years. Female sex and RP were independent predictors of PS according to the multivariate analysis. Maintaining and increasing muscle mass in patients with CLD may contribute toward improving physical QOL.
  • Kazuki Ohashi, Toru Ishikawa, Asami Hoshii, Tamaki Hokari, Mitsuyuki Suzuki, Yuta Mitobe, Etsuko Yamada, Hansani Madushika Abeywickrama, Yuko Kikuchi, Hirohito Noguchi, Hiroshi Hirosawa, Yu Koyama
    Journal of clinical medicine research 11 10 711 - 719 2019年10月 [査読有り][通常論文]
     
    Background: Sarcopenia is a prognostic factor for patients with liver cirrhosis and hepatocellular carcinoma, and it affects the onset of hepatic encephalopathy. Therefore, the prevention of sarcopenia contributes to the improvement of the prognosis of patients with chronic liver disease (CLD). We focused on changes of hand grip strength (HGS), one of the indicators of sarcopenia. However, there are little data investigating the impact of physical activity (PA) on HGS in patients with CLD. This study aimed to clarify whether PA contributes to the prevention of muscle weakness in patients with CLD. Methods: This was a prospective observational study. We examined the effect of PA on changes in HGS from the baseline to the endpoint in each group. Metabolic equivalents-hour/week (METs-h/w) was used to evaluate PA. In total, 183 outpatients with CLD were analyzed. We divided participants into four groups (low PA in younger patients (n = 20), high PA in younger patients (n = 33), low PA in elderly patients (n = 47), and high PA in elderly patients (n = 83)). Results: Fifty-eight percent of patients were men, and the median (interquartile range) age was 69.0 (63.0, 75.0) years. The most common etiology of liver disease was hepatitis C (38%). The frequency of living alone and low exercise habit was significantly high, and sarcopenia was more obvious in elderly patients with low PA than in those with high PA. Additionally, the elderly with low PA showed significantly reduced HGS compared to that of the elderly with high PA (-1.00 (-2.27, 0.55) kg vs. 0.10 (-1.40, 1.10) kg, P < 0.05). However, changes in HGS in younger patients were not significant (-0.02 (1.83, 1.47) kg vs. 0.25 (-2.45, 2.05) kg, P = 0.96). Logistic regression analyses identified PA as the independent factor for prevention of decrease in HGS (odds ratio: 1.91, 95% confidence interval: 1.00 - 3.62, P = 0.049). Conclusions: Young patients with low PA were characterized by a long sedentary time; however, there was no loss of HGS. In contrast, elderly patients with CLD and low PA had significantly reduced HGS compared to that in elderly patients with CLD and high PA.
  • Kazuki Ohashi, Toru Ishikawa, Asami Hoshi, Mitsuyuki Suzuki, Yuta Mitobe, Etsuko Yamada, Hansani Madushika Abeywickrama, Nao Seki, Chikayo Koyama, Hagiko Aoki, Yu Koyama
    Journal of clinical medicine research 10 12 920 - 927 2018年12月 [査読有り][通常論文]
     
    Background: Sarcopenia can affect the prognosis of patients with cirrhosis or hepatocellular carcinoma. Exercise therapy and nutritional therapy are carried out to prevent processing sarcopenia. In addition, changing lifestyle is also important. However, there are only few reports on the physical activities (PAs) and lifestyle of chronic liver disease patients and their association with sarcopenia. The aim of this study is to examine the relationship between sarcopenia in patients with chronic liver disease and both PA and lifestyle. Methods: A total of 214 out-patients with chronic liver disease were enrolled into the present study. All patients were evaluated for with or without sarcopenia based on the sarcopenia diagnostic criteria of the Japan Society of Hepatology. Then, patient's characteristics and laboratory parameters were divided into two groups with or without sarcopenia and compared. In continuous variable with significant difference in univariate analysis, cut-off value was calculated by receiver operating characteristic curve. We determined which factors were associated with sarcopenia in univariate analyses, and variables significant in the univariate analyses were entered in a multivariable logistic regression model. Results: Patients with chronic liver disease had a prevalence of sarcopenia of 12.6% in this study. Sarcopenia patients were older (76.48 ± 6.69 versus 66.97 ± 11.19 years old; P < 0.01), had lower body mass index (BMI) (20.84 ± 2.44 versus 23.76 ± 3.72 kg/m2; P < 0.01), lower PA (6.6 (2.34 - 19.90) versus 16.5 (6.60 - 41.23) metabolic equivalents (METs)-h/week; P < 0.01) and longer total time sitting and lying on the day (7.43 ± 4.09 versus 5.68 ± 3.17 h/day; P = 0.01); retirement status (81.5% versus 48.1%; P < 0.01) and low frequency of driving (40% versus 20%; P = 0.01) were higher in sarcopenia patients than in non-sarcopenia patients. The independent predictive factors of sarcopenia, analyzed with logistic regression, were age (odds ratio (OR): 5.89, 95% confidence interval (CI): 2.15 - 16.20; P < 0.01), BMI (OR: 4.77, 95% CI: 1.87 - 12.10; P < 0.01) and PA (OR: 3.65, 95% CI: 2.15 - 16.20; P < 0.01). Conclusion: Sarcopenia patients' lifestyle characteristics were longer sedentary time and low frequency of driving, high retirement. Independent predictive factors of sarcopenia were elderly, low BMI and low PA. For these patients, intervention in the lifestyle for prevention of sarcopenia may be effective for patients with chronic liver disease.
  • Hansani Madushika Abeywickrama, Yu Koyama, Mieko Uchiyama, Utako Shimizu, Yuka Iwasa, Etsuko Yamada, Kazuki Ohashi, Yuta Mitobe
    Nutrients 10 11 2018年10月27日 [査読有り][通常論文]
     
    Micronutrients include vitamins, minerals and, trace elements that are required in minute quantities but play a vital role in normal human growth, development and physiological functioning. Micronutrient deficiencies, also known as hidden hunger, are a global issue, with particularly high prevalence rates in developing countries. Currently, Sri Lanka is experiencing the double burden of over- and undernutrition. This review describes the micronutrient status of Sri Lanka based on results of national surveys and related articles published from 2000. The available data suggest a higher prevalence of iron, zinc, calcium, folate, and vitamin A deficiencies. The prevalence of iodine deficiency has declined gradually following the implementation of a universal salt iodization program. Iron deficiency is the most common cause of anemia and low red blood cell indices. Females are more vulnerable to micronutrient deficiencies than males. The coexistence of multiple micronutrient deficiencies and concurrent macro- and micronutrient deficiencies is common. Studies have shown an association between micronutrient deficiencies and different demographic, socioeconomic, and dietary factors. Therefore, there is a need for comprehensive studies, nutritional policies, and nationwide intervention programs in Sri Lanka to improve the micronutrient status of the population.
  • Ohashi K, Ishikawa T, Suzuki M, Abe H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, Hirosawa S, Kobayashi M, Hirosawa H, Sato K, Fukazawa T, Maruyama Y, Yoshida T
    Experimental and therapeutic medicine 15 1 970 - 976 2018年01月 [査読有り][通常論文]
     
    Interferon-free direct acting antiviral agent regimens for chronic hepatitis C (CHC) have been developed. These regimens have shown a high rate of sustained virologic response (SVR), and a reduction in side effects during treatment is also anticipated. However, the impact of the regimens on health-related quality of life (HRQOL) and side effects during treatment is not fully understood. The purpose of the present study was to evaluate HRQOL in the clinical course of patients with CHC receiving daclatasvir/asunaprevir (DCV/ASV) therapy using the Short Form-36 (SF-36) method. Twenty-eight patients with CHC receiving DCV/ASV therapy were analyzed in the present study, and HRQOL was measured by SF-36. Patients were asked to fill out the SF-36 prior to therapy (baseline), following 12 weeks of therapy, at the end of treatment and at SVR week 24 (SVR24) to evaluate HRQOL. Laboratory data were also investigated during the same period, and associations between these results and SF-36 were investigated. Aspartate aminotransferase, alanine aminotransferase, serum albumin, α-fetoprotein, platelet counts and Fibrosis (Fib)-4 index were all significantly improved at each time point when compared with baseline. With regard to alterations in HRQOL during therapy, the ≥70-year-old group displayed a significantly greater improvement in physical functioning during the period between baseline and 12 weeks when compared with the <70-year-old group. In the analysis of the SF-36 differences within each group, general health improved significantly in the ≥70-year-old group, as well as albumin levels. In addition, Fib-4-index significantly improved at all time points (12 and 24 weeks, and SVR24) when compared with baseline in the ≥70-year-old group. Therefore, DCV/ASV therapy may improve HRQOL and hepatic functional reserve, particularly in elderly patients.
  • Mitsuyuki Suzuki, Toru Ishikawa, Ai Sakuma, Satoshi Abe, Hiroko Abe, Fujiko Koyama, Tomomi Nakano, Aya Ueki, Hirohito Noguchi, Erina Hasegawa, Shiori Yamagata, Miki Kobayashi, Kazutaka Ohashi, Hiroshi Hirosawa, Takako Fukazawa, Yuka Maruyama, Toshiaki Yoshida
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 12 5 3353 - 3358 2016年11月 [査読有り][通常論文]
     
    The rate of sustained virologic response (SVR) has increased in patients with chronic hepatitis C (CHC; genotype 1) since triple treatment with pegylated interferon (PEG-IFN), ribavirin (RBV) and telaprevir (TVR) was included in Japanese health insurance. However, side effects such as high-grade anemia and skin disorders means it is important to investigate the extent to which quality of life (QOL) is maintained during treatment. The impact on health-related (HR) QOL, as a result of TVR-based triple treatment was investigated long-term (48 weeks) in 34 patients (18 men, 16 women) following TVR-based triple treatment, using the 36-item short form health survey (SF-36). While scores for physical health were significantly lower during treatment, an improvement was seen in patients who showed complete response to treatment from 12 weeks following treatment (P< 0.05). HRQOL improved significantly following completion of TVR-based triple treatment in these complete-responders, with higher scores compared with those prior to treatment. Anemia and skin symptoms appeared frequently during treatment and scores for physical health dropped. Particular care needs to be taken in regards to the management of side effects during TVR treatment. Further evaluations using the SF-36 may help in controlling doses to achieve SVR.

その他活動・業績

  • 慢性肝疾患患者に対するサルコペニア診断を目的としたcomputed tomographyによる基準値算出の検討
    星井 旭美, 石川 達, 大橋 和貴, 帆苅 環, 今井 径卓, 小林 功, 吉田 俊明 日本消化器病学会雑誌 118 (臨増大会) A700 -A700 2021年10月
  • 当院における慢性肝疾患患者の血清亜鉛値とプレサルコペニアの関連性について
    鈴木 光幸, 石川 達, 星井 旭美, 大橋 和貴, 廣澤 宏, 野口 博人, 吉田 俊明 日本消化器病学会雑誌 118 (臨増大会) A765 -A765 2021年10月
  • HAN Feng, ZHANG ZiHeng, 大橋和貴, ZHANG HongJian, 小笠原克彦 医療情報学連合大会論文集(CD-ROM) 41st 2021年
  • ZHANG Ziheng, HAN Feng, 大橋和貴, ZHANG Hongjian, 小笠原克彦 医療情報学連合大会論文集(CD-ROM) 41st 2021年
  • 大橋和貴, 坂東恭平, 小笠原克彦 医療情報学連合大会論文集(CD-ROM) 41st 2021年
  • 慢性肝疾患におけるL-carnitineの骨格筋量、骨密度への有用性
    大橋 和貴, 石川 達, 帆苅 環, 星井 旭美, 鈴木 光幸, 野口 博人, 廣澤 宏, 植木 文, 小林 美樹, 廣澤 詩織, 水科 美紀, 杉山 かえで, 今井 径卓, 吉田 俊明 日本消化器病学会雑誌 117 (臨増大会) A741 -A741 2020年10月
  • 慢性肝疾患患者の身体活動量とその関連要因
    大橋 和貴 日本慢性看護学会誌 14 (Suppl.) 72 -72 2020年09月
  • 慢性肝疾患におけるサルコペニア予防とメディカルスタッフの役割
    大橋 和貴 第72回 済生会学会 2020年02月 [査読無し][招待有り]
  • 胃切除術パスにおける消化管運動機能に対する処置介入の必要性
    本間 由佳, 簑口 紗織, 大橋 和貴, 羽田 千代子, 内藤 秀子, 高野 留美, 佐藤 志津子, 武者 信行, 車田 茂徳 日本クリニカルパス学会誌 21 (4) 416 -416 2019年12月 [査読無し][通常論文]
  • 大橋 和貴, 石川 達, 星井 旭美, 鈴木 光幸, 山田 悦子, 菊池 裕子, Abeywickrama Hansani, 水戸部 優太, 小山 千加代, 関 奈緒, 青木 萩子, 小山 諭 日本消化器病学会雑誌 116 (臨増大会) A803 -A803 2019年11月 [査読無し][通常論文]
  • 廣澤 宏, 石川 達, 今井 径卓, 阿部 弘子, 小山 富士子, 中野 ともみ, 植木 文, 長谷川 江梨名, 野口 博人, 大橋 和貴, 廣澤 詩織, 小林 美樹, 鈴木 光幸, 佐藤 かえで, 帆苅 環, 星井 旭美, 吉田 俊明 日本消化器病学会雑誌 116 (臨増大会) A804 -A804 2019年11月 [査読無し][通常論文]
  • 星井 旭美, 石川 達, 帆苅 環, 八巻 諒人, 大橋 和貴, 今井 径卓, 小林 功, 吉田 俊明 日本消化器病学会雑誌 116 (臨増大会) A848 -A848 2019年11月 [査読無し][通常論文]
  • 帆苅 環, 石川 達, 星井 旭美, 八巻 諒人, 大橋 和貴, 今井 径卓, 小林 功, 吉田 俊明 日本消化器病学会雑誌 116 (臨増大会) A848 -A848 2019年11月 [査読無し][通常論文]
  • 八巻 諒人, 石川 達, 帆苅 環, 星井 旭美, 大橋 和貴, 今井 径卓, 小林 功, 吉田 俊明 日本消化器病学会雑誌 116 (臨増大会) A849 -A849 2019年11月 [査読無し][通常論文]
  • Yuta Mitobe, Y Koyama, S Sakai, M Uchiyama, H Abeywickrama, E Yamada, K Ohashi, Y Kikuchi, M Nitta, T Honda, H Endo Clinical Nutrition 2019年09月 [査読有り][通常論文]
  • 水戸部優太, 小山諭, 内山美枝子, 大橋和貴, 山田悦子, ハンサニ アベイウィックレマ, 坂井さゆり, 菊池裕子, 森下慎一郎 外科と代謝・栄養 53 (3) 76 -76 2019年06月15日 [査読無し][通常論文]
  • 慢性肝疾患患者の身体活動量と握力の変化
    大橋和貴, 小山諭, 石川達, 星井旭美, 鈴木光幸, 水戸部優太, 山田悦子, 菊池裕子, Hansani Abeywickrama, 小山千加代, 関奈緒, 青木萩子 第6回日本サルコペニア・悪液質・消耗性疾患研究会 2019年04月 [査読無し][通常論文]
  • 重症患者への早期リハビリテーションの有効性と骨格筋指数を用いたICU-AW発症予測
    水戸部優太, 小山諭, 森下慎一郎, 大橋和貴, 山田悦子, Hansani Abeywickrama, 菊池裕子, 坂井さゆり, 内山美枝子 第6回日本サルコペニア・悪液質消耗性疾患研究会 2019年04月 [査読無し][通常論文]
  • 植木文, 石川達, 今井径卓, 阿部弘子, 小山富士子, 中野ともみ, 長谷川江梨名, 野口博人, 大橋和貴, 廣澤詩織, 小林美樹, 丸山由華, 廣澤宏, 鈴木光幸, 深澤尚子, 佐藤かえで, 吉田俊明 肝臓 59 (Supplement 3) A902 2018年11月25日 [査読無し][通常論文]
  • C型肝炎に対するインターフェロンフリー治療症例のSF-36によるQOL評価の検討
    宗形 美祐, 石川 達, 野口 博人, 阿部 弘子, 小山 富士子, 中野 ともみ, 植木 文, 廣澤 詩織, 小林 美樹, 長谷川 江梨名, 大橋 和貴, 丸山 由華, 廣澤 宏, 鈴木 光幸, 深澤 尚子, 吉田 俊明 日本消化器病学会雑誌 115 (臨増大会) A736 -A736 2018年10月 [査読無し][通常論文]
  • プレサルコペニア合併慢性肝疾患患者のQOLの検討
    大橋 和貴, 石川 達, 星井 旭美, 鈴木 光幸, 阿部 弘子, 中野 ともみ, 小山 富士子, 植木 文, 廣澤 詩織, 小林 美樹, 野口 博人, 宗形 美佑, 佐藤 かえで, 廣澤 宏, 今井 径卓, 吉田 俊明 日本消化器病学会雑誌 115 (臨増大会) A809 -A809 2018年10月 [査読無し][通常論文]
  • 慢性肝疾患患者におけるサルコペニア合併例の特徴
    大橋 和貴, 石川 達, 星井 旭美, 小山 諭, 青木 萩子 日本消化器病学会雑誌 115 (臨増大会) A809 -A809 2018年10月 [査読無し][通常論文]
  • 慢性肝疾患患者のかゆみに対するナルフラフィンの治療効果とQOLの検討
    鈴木 光幸, 石川 達, 廣澤 宏, 大橋 和貴, 小山 富士子, 吉田 俊明 日本消化器病学会雑誌 115 (臨増大会) A810 -A810 2018年10月 [査読無し][通常論文]
  • 大橋和貴, 石山綾 日本医療マネジメント学会雑誌 19 (Supplement) 303 2018年05月07日 [査読無し][通常論文]
  • C型肝疾患に対するDaclatasvir/Asunaprevir療法におけるSF-36を用いたQOL評価の検討
    大橋 和貴, 石川 達, 今井 径卓, 阿部 弘子, 中野 ともみ, 植木 文, 小山 富士子, 野口 博人, 廣澤 詩織, 小林 美樹, 高 昌良, 吉田 俊明 日本消化器病学会雑誌 114 (臨増大会) A845 -A845 2017年09月 [査読無し][通常論文]
  • インターフェロンフリーに対するSF-36によるQOL評価の検討
    野口 博人, 石川 達, 阿部 弘子, 小山 富士子, 中野 ともみ, 植木 文, 山形 詩織, 小林 美樹, 長谷川 江梨名, 大橋 和貴, 丸山 由華, 廣澤 宏, 鈴木 光幸, 深澤 尚子, 佐藤 かえで, 吉田 俊明 日本消化器病学会雑誌 114 (臨増大会) A846 -A846 2017年09月 [査読無し][通常論文]
  • 慢性肝疾患に対するナルフラフィン投与患者のそう痒感評価とQOL改善効果についての検討
    廣澤 詩織, 石川 達, 今井 径卓, 阿部 弘子, 小山 富士子, 中野 ともみ, 植木 文, 野口 博人, 小林 美樹, 長谷川 江梨名, 大橋 和貴, 丸山 由華, 廣澤 宏, 鈴木 光幸, 深澤 尚子, 佐藤 かえで, 吉田 俊明 日本消化器病学会雑誌 114 (臨増大会) A854 -A854 2017年09月 [査読無し][通常論文]
  • 慢性肝疾患患者におけるChronic liver disease questionnairesと包括的QOL評価であるSF-36の相関性の評価
    野口 博人, 石川 達, 阿部 弘子, 小山 富士子, 中野 ともみ, 植木 文, 山形 詩織, 小林 美樹, 長谷川 江梨名, 大橋 和貴, 丸山 由華, 廣澤 宏, 鈴木 光幸, 深澤 尚子, 佐藤 かえで, 吉田 俊明 日本消化器病学会雑誌 114 (臨増大会) A855 -A855 2017年09月 [査読無し][通常論文]
  • 大橋和貴, 石川達, 植木文, 小林美樹, 山形詩織, 深澤尚子, 阿部弘子, 小山富士子, 中野ともみ, 野口博人, 鈴木光幸, 廣澤宏, 丸山由華 肝臓 57 (Supplement 3) A769 2016年10月25日 [査読無し][通常論文]
  • 鈴木光幸, 石川達, 廣澤宏, 大橋和貴, 吉田俊明 肝臓 57 (Supplement 3) A766 2016年10月25日 [査読無し][通常論文]
  • 大橋和貴, 石川達, 小林美樹, 山形詩織 肝臓 57 (Supplement 3) A774 2016年10月25日 [査読無し][通常論文]
  • 植木文, 石川達, 丸山由華, 阿部弘子, 小山富士子, 中野ともみ, 野口博人, 長谷川江梨名, 小林美樹, 山形詩織, 大橋和貴, 廣澤宏, 鈴木光幸, 深澤尚子, 吉田俊明 肝臓 57 (Supplement 3) A767 2016年10月25日 [査読無し][通常論文]
  • IFN-based第二世代DAA3剤併用療法に対するSF-36によるQOL評価の検討
    大橋 和貴, 石川 達, 阿部 聡司, 阿部 弘子, 中野 ともみ, 植木 文, 小山 富士子, 長谷川 江梨名, 野口 博人, 山形 詩織, 小林 美樹, 渡邊 貴之, 吉田 俊明 日本消化器病学会雑誌 113 (臨増大会) A737 -A737 2016年09月 [査読無し][通常論文]
  • Daclatasvir/Asunaprevir療法におけるSF-36を用いたQOL評価の検討
    大橋 和貴, 石川 達, 阿部 聡司, 阿部 弘子, 中野 ともみ, 植木 文, 小山 富士子, 長谷川 江梨名, 野口 博人, 山形 詩織, 小林 美樹, 渡邊 貴之, 吉田 俊明 日本消化器病学会雑誌 113 (臨増大会) A739 -A739 2016年09月 [査読無し][通常論文]
  • 肝予備能改善を目ざした分岐鎖アミノ酸(branched-chain amino acids;BCAA)含有経腸栄養剤アドヒアランス向上のための服用評価
    小林 美樹, 石川 達, 阿部 弘子, 小山 富士子, 中野 ともみ, 植木 文, 野口 博人, 長谷川 江梨名, 山形 詩織, 大橋 和貴, 丸山 由華, 廣澤 宏, 鈴木 光幸, 深沢 尚子, 吉田 俊明 日本消化器病学会雑誌 113 (臨増大会) A754 -A754 2016年09月 [査読無し][通常論文]
  • レボカルニチン製剤投与中患者のSF-36を用いたQOL評価の検討
    植木 文, 石川 達, 阿部 聡司, 大橋 和貴, 阿部 弘子, 中野 ともみ, 小山 富士子, 長谷川 江梨名, 野口 博人, 山形 詩織, 小林 美樹, 渡邊 貴之, 吉田 俊明 日本消化器病学会雑誌 113 (臨増大会) A754 -A754 2016年09月 [査読無し][通常論文]
  • 慢性肝疾患患者におけるChronic liver disease questionnaires(CLDQ)と包括的QOL評価であるSF-36の相関性の検討
    野口 博人, 石川 達, 阿部 弘子, 小山 富士子, 中野 ともみ, 植木 文, 小林 美樹, 長谷川 江梨名, 山形 詩織, 大橋 和貴, 丸山 由華, 廣澤 宏, 鈴木 光幸, 深沢 尚子, 吉田 俊明 日本消化器病学会雑誌 113 (臨増大会) A755 -A755 2016年09月 [査読無し][通常論文]
  • 慢性肝疾患に対する肝外合併症であるそう痒感の実態調査
    山形 詩織, 石川 達, 阿部 聡司, 阿部 弘子, 小山 富士子, 中野 ともみ, 植木 文, 野口 博人, 小林 美樹, 長谷川 江梨名, 大橋 和貴, 丸山 由華, 廣澤 宏, 鈴木 光幸, 深澤 尚子, 吉田 俊明 日本消化器病学会雑誌 113 (臨増大会) A755 -A755 2016年09月 [査読無し][通常論文]
  • 植木文, 石川達, 阿部聡司, 大橋和貴, 阿部弘子, 中野ともみ, 小山富士子, 長谷川江梨名, 野口博人, 山形詩織, 小林美樹, 渡邊貴之, 吉田俊明 日本消化器病学会大会(Web) 58th ROMBUNNO.SHOP‐404 (WEB ONLY) 2016年 [査読無し][通常論文]
  • 山形詩織, 石川達, 阿部聡司, 阿部弘子, 小山富士子, 中野ともみ, 植木文, 野口博人, 小林美樹, 長谷川江梨名, 大橋和貴, 丸山由華, 廣澤宏, 鈴木光幸, 深澤尚子, 吉田俊明 日本消化器病学会大会(Web) 58th ROMBUNNO.SHOP‐406 (WEB ONLY) 2016年 [査読無し][通常論文]
  • 大橋和貴, 石川達, 阿部聡司, 阿部弘子, 阿部弘子, 中野ともみ, 植木文, 小山富士子, 長谷川江梨名, 野口博人, 山形詩織, 小林美樹, 渡邊貴之, 吉田俊明 日本消化器病学会大会(Web) 58th ROMBUNNO.SHOP‐341 (WEB ONLY) 2016年 [査読無し][通常論文]
  • 大橋和貴 新潟医学会雑誌 129 (10) 617 2015年10月10日 [査読無し][通常論文]
  • 山形詩織, 石川達, 阿部弘子, 小山富士子, 中野ともみ, 植木文, 野口博人, 長谷川江梨名, 小林美樹, 大橋和貴, 廣澤宏, 丸山由華, 鈴木光幸, 深澤尚子, 吉田俊明 肝臓 56 (Supplement 2) A789 2015年09月10日 [査読無し][通常論文]
  • 野口博人, 石川達, 阿部弘子, 小山富士子, 中野ともみ, 植木文, 長谷川江梨名, 小林美樹, 山形詩織, 大橋和貴, 丸山由華, 廣澤宏, 鈴木光幸, 深澤尚子, 吉田俊明 肝臓 56 (Supplement 2) A789 2015年09月10日 [査読無し][通常論文]
  • 岩野知子, 石川達, 山形詩織, 小林美樹, 大橋和貴, 金田藍子, 羽田千代子, 佐久間愛, 阿部聡司, 吉田俊明 日本消化器病学会大会(Web) 57th (臨増大会) SHOP‐332 (WEB ONLY) -A904 2015年09月 [査読無し][通常論文]

共同研究・競争的資金等の研究課題

  • GISを用いた訪問看護のアクセシビリティの将来推計と可視化
    日本学術振興会:科学研究費助成事業 基盤研究(C)
    研究期間 : 2022年04月 -2025年03月 
    代表者 : 大橋 和貴
  • 文部科学省:科学研究助成費事業 研究活動スタート支援
    研究期間 : 2019年09月 -2021年03月 
    代表者 : 大橋 和貴


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.